Trials / Completed
CompletedNCT05904730
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Lynkcell Europe · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Clinical Trial is investigating the potential efficacy of axitinib after genetic testing in BRCA 1/2 Mutation patients, regardless of HER2 expression, who have progressed after at least one line of standard treatment or for whom there is no consensus treatment approach. The use of Axitinib may help physicians plan for more effective patient care in combination with existing treatment protocols.
Detailed description
This Clinical Trial is investigating the potential efficacy of axitinib after genetic testing in BRCA 1/2 Mutation patients, regardless of HER2 expression, who have progressed after at least one line of standard treatment or for whom there is no consensus treatment approach. The use of Axitinib may help physicians plan for more effective patient care in combination with existing treatment protocols. The addition of Axitinib to existing treatment protocols and to fractionated irradiation without functional normalization of the tumor vasculature can significantly improve response to therapy, contributing to the breakdown of the metabolic symbiosis of adaptive drug resistance.
Conditions
- Breast Cancer
- Ovarian Cancer
- Breast Neoplasms
- Ovarian Neoplasms
- BRCA Mutation
- HER2-positive Breast Cancer
- HER2-negative Breast Cancer
- HER-2 Protein Overexpression
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Axitinib | The starting dose of axitinib is 5 mg twice daily by mouth with meals. (reception is desirable at the same time every day) |
Timeline
- Start date
- 2023-07-11
- Primary completion
- 2024-11-09
- Completion
- 2024-12-26
- First posted
- 2023-06-15
- Last updated
- 2024-12-30
Locations
2 sites across 1 country: Ukraine
Source: ClinicalTrials.gov record NCT05904730. Inclusion in this directory is not an endorsement.